Foglia & Partners, with a team coordinated by Giuliano Foglia and Matteo Carfagnini and composed of Francesco Capogrossi and Emanuele Gentile, assisted the pharmaceutical group Alfasigma by taking care of the tax aspects of the agreement to acquire the Jyseleca business, the trade name of the drug Filgotinib for the treatment of rheumatoid arthritis, from Galapagos, a Belgian company listed on the Euronext and NASDAQ markets.
As a result of the agreement, Alfasigma will acquire the entire Jyseleca-related business, including marketing authorizations in Europe and the United Kingdom, commercial, medical affairs and development activities, and approximately 400 Galapagos locations in 14 countries.